日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Characterization of breakthrough hemolysis events observed in the phase 3 randomized studies of ravulizumab versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria

对 ravulizumab 与 eculizumab 治疗阵发性睡眠性血红蛋白尿成人患者的 3 期随机研究中观察到的突破性溶血事件进行表征

期刊:Haematologica
影响因子:7.9
doi:10.3324/haematol.2019.236877
Brodsky, Robert A; Peffault de Latour, Régis; Rottinghaus, Scott T; Röth, Alexander; Risitano, Antonio M; Weitz, Ilene C; Hillmen, Peter; Maciejewski, Jaroslaw P; Szer, Jeff; Lee, Jong Wook; Kulasekararaj, Austin G; Volles, Lori; Damokosh, Andrew I; Ortiz, Stephan; Shafner, Lori; Liu, Peng; Hill, Anita; Schrezenmeier, Hubert
发表日期：2021
文献求助 收藏

DOT Diary: Developing a Novel Mobile App Using Artificial Intelligence and an Electronic Sexual Diary to Measure and Support PrEP Adherence Among Young Men Who Have Sex with Men

DOT日记：开发一款利用人工智能和电子性爱日记的新型移动应用程序，以衡量和支持男男性行为者服用暴露前预防药物（PrEP）的依从性

期刊:Aids and Behavior
影响因子:2.4
doi:10.1007/s10461-020-03054-2
Liu, Albert Y; Laborde, Nicole D; Coleman, Kenneth; Vittinghoff, Eric; Gonzalez, Rafael; Wilde, Gretchen; Thorne, Annie L; Ikeguchi, Ed; Shafner, Laura; Sunshine, Lauren; van der Straten, Ariane; Siegler, Aaron J; Buchbinder, Susan
发表日期：2021
文献求助 收藏

Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor-experienced adult patients with PNH: the 302 study

在既往接受过C5抑制剂治疗的PNH成人患者中，Ravulizumab (ALXN1210) 与 eculizumab 的比较：302 研究

期刊:Blood
影响因子:23.1
doi:10.1182/blood-2018-09-876805
Kulasekararaj, Austin G; Hill, Anita; Rottinghaus, Scott T; Langemeijer, Saskia; Wells, Richard; Gonzalez-Fernandez, F Ataulfo; Gaya, Anna; Lee, Jong Wook; Gutierrez, Emilio Ojeda; Piatek, Caroline I; Szer, Jeff; Risitano, Antonio; Nakao, Shinji; Bachman, Eric; Shafner, Lori; Damokosh, Andrew I; Ortiz, Stephan; Röth, Alexander; Peffault de Latour, Regis
发表日期：2019
文献求助 收藏

Ravulizumab (ALXN1210) in patients with paroxysmal nocturnal hemoglobinuria: results of 2 phase 1b/2 studies

Ravulizumab (ALXN1210)治疗阵发性睡眠性血红蛋白尿症患者：两项1b/2期研究的结果

期刊:Blood Advances
影响因子:7.1
doi:10.1182/bloodadvances.2018020644
Röth, Alexander; Rottinghaus, Scott T; Hill, Anita; Bachman, Eric S; Kim, Jin Seok; Schrezenmeier, Hubert; Terriou, Louis; Urbano-Ispizua, Álvaro; Wells, Richard A; Jang, Jun Ho; Kulasekararaj, Austin G; Szer, Jeff; Aguzzi, Rasha; Damokosh, Andrew I; Shafner, Lori; Lee, Jong Wook
发表日期：2018
文献求助 收藏

Use of a Novel Artificial Intelligence Platform on Mobile Devices to Assess Dosing Compliance in a Phase 2 Clinical Trial in Subjects With Schizophrenia

在针对精神分裂症患者的二期临床试验中，利用移动设备上的新型人工智能平台评估给药依从性

期刊:Jmir Mhealth and Uhealth
影响因子:6.2
doi:10.2196/mhealth.7030
Bain, Earle E; Shafner, Laura; Walling, David P; Othman, Ahmed A; Chuang-Stein, Christy; Hinkle, John; Hanina, Adam
精神分裂症
神经科学
发表日期：2017
文献求助 收藏